• Product nameAnti-p63 antibody
    See all p63 primary antibodies
  • Description
    Rabbit polyclonal to p63
  • SpecificityThis antibody detects endogenous levels of total p63 protein.
  • Tested applicationsSuitable for: IHC-Fr, ELISA, WB, IHC-Pmore details
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    Synthetic peptide derived from human p63. (Peptide available as ab153667.)

  • Positive control
    • Cos7 cell extract.



Our Abpromise guarantee covers the use of ab53039 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-Fr 1/250.
ELISA 1/20000.
WB 1/500 - 1/1000. Detects a band of approximately 77 kDa (predicted molecular weight: 77 kDa).Can be blocked with p63 peptide (ab153667).
IHC-P 1/200.


  • FunctionActs as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge.
  • Tissue specificityWidely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type isoforms. Isoform 10 is predominantly expressed in skin squamous cell carcinomas, but not in normal skin tissues.
  • Involvement in diseaseDefects in TP63 are the cause of acro-dermato-ungual-lacrimal-tooth syndrome (ADULT syndrome) [MIM:103285]; a form of ectodermal dysplasia. Ectodermal dysplasias (EDs) constitute a heterogeneous group of developmental disorders affecting tissues of ectodermal origin. EDs are characterized by abnormal development of two or more ectodermal structures such as hair, teeth, nails and sweat glands, with or without any additional clinical sign. Each combination of clinical features represents a different type of ectodermal dysplasia. ADULT syndrome involves ectrodactyly, syndactyly, finger- and toenail dysplasia, hypoplastic breasts and nipples, intensive freckling, lacrimal duct atresia, frontal alopecia, primary hypodontia, and loss of permanent teeth. ADULT differs significantly from EEC3 syndrome by the absence of facial clefting.
    Defects in TP63 are the cause of ankyloblepharon-ectodermal defects-cleft lip/palate (AEC) [MIM:106260]. AEC is an autosomal dominant condition characterized by congenital ectodermal dysplasia with coarse, wiry, sparse hair, dystrophic nails, slight hypohidrosis, scalp infections, ankyloblepharon filiform adnatum, maxillary hypoplasia, hypodontia and cleft lip/palate.
    Defects in TP63 are the cause of ectrodactyly-ectodermal dysplasia-cleft lip/palate syndrome type 3 (EEC3) [MIM:604292]. EEC3 is an autosomal dominant syndrome characterized by ectrodactyly of hands and feet, ectodermal dysplasia and facial clefting.
    Defects in TP63 are the cause of split-hand/foot malformation type 4 (SHFM4) [MIM:605289]. Split-hand/split-foot malformation is a limb malformation involving the central rays of the autopod and presenting with syndactyly, median clefts of the hands and feet, and aplasia and/or hypoplasia of the phalanges, metacarpals, and metatarsals. There is restricted overlap between the mutational spectra of EEC3 and SHFM4.
    Defects in TP63 are the cause of limb-mammary syndrome (LMS) [MIM:603543]. LMS is characterized by ectrodactyly, cleft palate and mammary-gland abnormalities.
    Note=Defects in TP63 are a cause of cervical, colon, head and neck, lung and ovarian cancers.
    Defects in TP63 are a cause of ectodermal dysplasia Rapp-Hodgkin type (EDRH) [MIM:129400]; also called Rapp-Hodgkin syndrome or anhidrotic ectodermal dysplasia with cleft lip/palate. Ectodermal dysplasia defines a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. EDRH is characterized by the combination of anhidrotic ectodermal dysplasia, cleft lip, and cleft palate. The clinical syndrome is comprised of a characteristic facies (narrow nose and small mouth), wiry, slow-growing, and uncombable hair, sparse eyelashes and eyebrows, obstructed lacrimal puncta/epiphora, bilateral stenosis of external auditory canals, microsomia, hypodontia, cone-shaped incisors, enamel hypoplasia, dystrophic nails, and cleft lip/cleft palate.
    Defects in TP63 are the cause of non-syndromic orofacial cleft type 8 (OFC8) [MIM:129400]. Non-syndromic orofacial cleft is a common birth defect consisting of cleft lips with or without cleft palate. Cleft lips are associated with cleft palate in two-third of cases. A cleft lip can occur on one or both sides and range in severity from a simple notch in the upper lip to a complete opening in the lip extending into the floor of the nostril and involving the upper gum.
  • Sequence similaritiesBelongs to the p53 family.
    Contains 1 SAM (sterile alpha motif) domain.
  • DomainThe transactivation inhibitory domain (TID) can interact with, and inhibit the activity of the N-terminal transcriptional activation domain of TA*-type isoforms.
  • Post-translational
    May be sumoylated.
    Ubiquitinated. Polyubiquitination involves WWP1 and leads to proteasomal degradation of this protein.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • AIS antibody
    • Amplified in squamous cell carcinoma antibody
    • B(p51A) antibody
    • B(p51B) antibody
    • Chronic ulcerative stomatitis protein antibody
    • CUSP antibody
    • DN p63 alpha 1 antibody
    • DNp63 antibody
    • EEC3 antibody
    • id:ibd3516 antibody
    • Keratinocyte transcription factor antibody
    • Keratinocyte transcription factor KET antibody
    • KET antibody
    • LMS antibody
    • MGC115972 antibody
    • MGC192897 antibody
    • NBP antibody
    • OFC8 antibody
    • OTTHUMP00000209732 antibody
    • OTTHUMP00000209733 antibody
    • OTTHUMP00000209734 antibody
    • OTTHUMP00000209735 antibody
    • OTTHUMP00000209737 antibody
    • OTTHUMP00000209738 antibody
    • OTTHUMP00000209739 antibody
    • OTTHUMP00000209740 antibody
    • OTTHUMP00000209741 antibody
    • OTTHUMP00000209742 antibody
    • OTTHUMP00000209743 antibody
    • OTTHUMP00000209744 antibody
    • p40 antibody
    • p51 antibody
    • P51/P63 antibody
    • p53-related protein p63 antibody
    • p53CP antibody
    • p63 antibody
    • P63_HUMAN antibody
    • p73H antibody
    • p73L antibody
    • RHS antibody
    • SHFM4 antibody
    • TAp63alpha antibody
    • TP53CP antibody
    • TP53L antibody
    • TP63 antibody
    • TP73L antibody
    • Transformation related protein 63 antibody
    • Transformation-related protein 63 antibody
    • Trp53rp1 antibody
    • Trp63 antibody
    • Tumor protein 63 antibody
    • Tumor protein p53-competing protein antibody
    • Tumor protein p53-like antibody
    • Tumor protein p63 antibody
    • Tumor protein p63 deltaN isoform delta antibody
    • Tumor protein p73 antibody
    • Tumor protein p73-like antibody
    see all

Anti-p63 antibody images

  • All lanes : Anti-p63 antibody (ab53039) at 1/500 dilution

    Lane 1 : Cos7 cell extract
    Lane 2 : Cos7 cell extract with peptide at 1 µg/ml

    Predicted band size : 77 kDa
    Observed band size : 77 kDa

  • developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 77 kDa

    Exposure time : 10 seconds

References for Anti-p63 antibody (ab53039)

This product has been referenced in:
  • Derby BM  et al. Adipose-derived stem cell to epithelial stem cell transdifferentiation: a mechanism to potentially improve understanding of fat grafting's impact on skin rejuvenation. Aesthet Surg J 34:142-53 (2014). Read more (PubMed: 24334307) »
  • Haro E  et al. Sp6 and Sp8 Transcription Factors Control AER Formation and Dorsal-Ventral Patterning in Limb Development. PLoS Genet 10:e1004468 (2014). IHC-P ; Mouse . Read more (PubMed: 25166858) »

See all 11 Publications for this product

Product Wall

Application Immunocytochemistry
Blocking step BSA as blocking agent for 15 minute(s) · Concentration: 1% · Temperature: 21°C
Sample Equus Cultured Cells (Equine Epidermal-derived stem cells)
Specification Equine Epidermal-derived stem cells
Permeabilization Yes - Triton X
Fixative Formaldehyde

Dr. Jan Spaas

Verified customer

Submitted Oct 08 2013

This antibody reacts with human p63 (isforms 1, 2, 9, 10, 11, and 12), mouse p63 (isoforms 1 and 2), and rat p63 (isoforms 1, 2, and 7).

I hope this information is helpful to you. Please do not hesitate to contact us if you need any ...

Read More

Thank you for contacting us.

I have been in contact with the lab regarding your request. We have been able to add the immunizing peptide for ab53039 as requested. This has been added as p63 peptide (ab153667). More information about this p...

Read More

Thank you for your inquiry.

I have checked the immunogen sequences of the BCRP/ABCG2 and p53 antibodies we have that are tested in IHC-Fr with the rabbit sequences for these proteins.

I am sorry to confirm that regrettably, the al...

Read More

Thank you for contacting us.

Your credit note ID is xxx.

I am sorry that this antibody did not perform as stated on the datasheet. If payment has already been made on the original order and you wish to receive a refund, please ask...

Read More

Thank you for the additional information.

The conditions you have been using have worked for other customers in the past, thus, I believe your protocol is fine. I am not certain why no specific staining was observed - it could be that the via...

Read More

Thank you for contacting us.
I am sorry to hear that the antibody is notworkingas expected.

1) Could you please let me know which problem you specifically have encountered: no staining, high background, incorrectstaining location?

Read More

Thank you for contacting us.

Here please find the information about our testing discount program. Below I also include information about our Abpromise guarantee.

For UNTESTED species and/or applications, we have established a testi...

Read More
Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Mouse Tissue sections (Mammary Gland)
Specification Mammary Gland
Fixative Paraformaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: Citrate Buffer
Permeabilization Yes - 0.1% Triton X-100
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 23°C

Abcam user community

Verified customer

Submitted Mar 08 2012

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Frozen sections)
Sample Mouse Tissue sections (Mammary Gland)
Specification Mammary Gland
Fixative Paraformaldehyde
Permeabilization Yes - 0.1% Triton X-100
Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 1% · Temperature: 23°C

Abcam user community

Verified customer

Submitted Feb 22 2012